Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.46 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28202332 | 0.94 | HDAC1 (0.42) | HDAC1HDAC2CHRM1CHRM3ADRA1A | |
| SCHEMBL7217708 | 0.91 | CA2 (0.47) | HDAC1HDAC2CHRM1CHRM3ADRA1A | |
| SCHEMBL22501908 | 0.90 | CA1 (0.43) | HDAC1HDAC2CHRM1CHRM3ADRA1A | |
| SCHEMBL28497754 | 0.89 | CA2 (0.46) | HDAC1HDAC2HDAC7HDAC8HDAC6 | |
| SCHEMBL28257521 | 0.89 | MAPT (0.42) | HDAC1HDAC2CHRM1CHRM3ADRA1A | |
| SCHEMBL28148945 | 0.86 | RECQL (0.42) | HDAC1HDAC2CHRM1CHRM3ADRA1A | |
| SCHEMBL11164510 | 0.85 | HDAC1 (0.42) | HDAC1HDAC2CHRM1CHRM3ADRA1A | |
| SCHEMBL6893798 | 0.84 | CA2 (0.48) | CA1CA2GRIK1SLC1A2SLC1A1 | |
| SCHEMBL6894718 | 0.84 | CA2 (0.48) | CA1CA2GRIK1SLC1A2SLC1A1 | |
| SCHEMBL18383513 | 0.84 | CA2 (0.48) | CA1CA2GRIK1SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250249108-A1 | PRODRUGS FOR CANCER TREATMENT | GATC Health Corp (US) | 2025-08-07 | — | — | US | disclosed |
| EP-4504211-A2 | PRODRUGS FOR CANCER TREATMENT | GATC Health Corp (US) | 2025-02-12 | — | — | EP | disclosed |
| WO-2023196668-A2 | PRODRUGS FOR CANCER TREATMENT | GATC Health Corp (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230150941-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2023-05-18 | — | — | US | disclosed |
| US-20230150941-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2023-05-18 | — | — | US | disclosed |
| WO-2023056606-A1 | VALPROATE (VPA) COMPOUNDS FOR USE IN TREATING SPINOCEREBELLAR ATAXIA TYPE 1 (SCA1) | HANGZHOU JIJING PHARMACEUTICAL TECHNOLOGY LIMITED (CN) | 2023-04-13 | — | — | WO | disclosed |
| WO-2023056948-A1 | METHODS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 1 (SCA1) WITH VALPROATE (VPA) COMPOUNDS | HANGZHOU JIJING PHARMACEUTICAL TECHNOLOGY LIMITED (CN) | 2023-04-13 | — | — | WO | disclosed |
| US-20220133740-A1 | VALPROIC ACID COMPOUNDS AND WNT AGONISTS FOR TREATING EAR DISORDERS | Frequency Therapeutics, Inc. (US) | 2022-05-05 | — | — | US | disclosed |
| EP-3920885-A1 | VALPROIC ACID COMPOUNDS AND WNT AGONISTS FOR TREATING EAR DISORDERS | Frequency Therapeutics, Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| US-10822306-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | ALKERMES PHARMA IRELAND LIMITED (IE) | 2020-11-03 | — | — | US | disclosed |
| US-20110166194-A1 | Asenapine Prodrugs | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166194-A1 | Asenapine Prodrugs | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166128-A1 | Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110015156-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | ALKERMES, INC. | 2011-01-20 | — | — | US | disclosed |
| US-20110015156-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | ALKERMES, INC. | 2011-01-20 | — | — | US | disclosed |
| US-20110003828-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | ALKERMES, INC. | 2011-01-06 | — | — | US | disclosed |
| US-20110003828-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | ALKERMES, INC. | 2011-01-06 | — | — | US | disclosed |
| WO-2010080581-A2 | VALPROIC ACID, DERIVATIVES, ANALOGUES, AND COMPOSITIONS INCLUDING SAME AND METHODS FOR THEIR THERAPEUTIC USE | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) | 2010-07-15 | — | — | WO | disclosed |
| US-6667285-B1 | Branched-chain carboxylic acid monoalkyl ester with outstanding hydrolytic stability | NEW JAPAN CHEMICAL CO., LTD. (JP) | 2003-12-23 | — | — | US | disclosed |
| EP-1225213-A1 | LUBRICATING OIL FOR REFRIGERATOR, HYDRAULIC FLUID COMPOSITION FOR REFRIGERATOR AND METHOD FOR LUBRICATION OF REFRIGERATOR | NEW JAPAN CHEMICAL CO.,LTD. (JP) | 2002-07-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166194-A1 | Asenapine Prodrugs | GRIN1, SCN1B, GRIN2B | HDAC1 267/4885HDAC2 945/4885CHRM1 39/4885 |
| US-20230150941-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | HDAC1 267/4885HDAC2 390/4885CHRM1 1131/4885 |
| US-20110166128-A1 | Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders | HTR5A, HTR2C, HTR2B | HDAC1 523/4885HDAC2 158/4885CHRM1 2761/4885 |
| US-20220133740-A1 | VALPROIC ACID COMPOUNDS AND WNT AGONISTS FOR TREATING EAR DISORDERS | WNT3A, WNT1, WNT3 | HDAC1 226/4885HDAC2 191/4885CHRM1 3163/4885 |
| US-20110003828-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | SI, NAAA, NIT2 | HDAC1 117/4885HDAC2 306/4885CHRM1 2747/4885 |
| US-10822306-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | GABBR1, GABBR2, GABRE | HDAC1 267/4885HDAC2 390/4885CHRM1 1131/4885 |
| US-20110015156-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | HDAC1 267/4885HDAC2 390/4885CHRM1 1131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.